APA

Kelaidi C., Beyne-Rauzy O., Braun T., Sapena R., Cougoul P., Adès L., Pillard F., Lamberto C., Lambert C., Charniot J. C., Guerci A., Choufi B., Stamatoullas A., Slama B., De Renzis B., Ame S., Damaj G., Boyer F., Chaury M. P., Legros L., Cheze S., Testu A., Gyan E., Béné M. C., Rose C., Dreyfus F. & Fenaux P. (20130528). High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. : Annals of hematology.

Chicago

Kelaidi C, Beyne-Rauzy O, Braun T, Sapena R, Cougoul P, Adès L, Pillard F, Lamberto C, Lambert C, Charniot J C, Guerci A, Choufi B, Stamatoullas A, Slama B, De Renzis B, Ame S, Damaj G, Boyer F, Chaury M P, Legros L, Cheze S, Testu A, Gyan E, Béné M C, Rose C, Dreyfus F and Fenaux P. 20130528. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. : Annals of hematology.

Harvard

Kelaidi C., Beyne-Rauzy O., Braun T., Sapena R., Cougoul P., Adès L., Pillard F., Lamberto C., Lambert C., Charniot J. C., Guerci A., Choufi B., Stamatoullas A., Slama B., De Renzis B., Ame S., Damaj G., Boyer F., Chaury M. P., Legros L., Cheze S., Testu A., Gyan E., Béné M. C., Rose C., Dreyfus F. and Fenaux P. (20130528). High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. : Annals of hematology.

MLA

Kelaidi C, Beyne-Rauzy O, Braun T, Sapena R, Cougoul P, Adès L, Pillard F, Lamberto C, Lambert C, Charniot J C, Guerci A, Choufi B, Stamatoullas A, Slama B, De Renzis B, Ame S, Damaj G, Boyer F, Chaury M P, Legros L, Cheze S, Testu A, Gyan E, Béné M C, Rose C, Dreyfus F and Fenaux P. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. : Annals of hematology. 20130528.